MarkCrean

Partner

Sydney + 61.2.8272.0710

Connect:

Share

Mark Crean, who leads the Firm's Australian M&A team, has more than 20 years of experience in M&A, restructurings, and private equity. He is highly accomplished at helping clients on complex transactions and finding solutions to difficult issues. He covers many industry sectors, particularly financial services and financial institutions, media, telecommunications, funds, and real estate.

Prior to joining Jones Day in 2015, Mark was deputy senior partner at a leading international law firm. Prior to that, he was chair of one of Australia's preeminent law firms and instrumental in negotiating their international merger. In 2006, he was seconded as group general counsel to ASX-listed, global real estate and development group Lend Lease Corporation at the request of its CEO. When Mark won the Lawyers Weekly "Dealmaker Award" at the 2013 Australian Law Awards, a client was quoted saying: "in the heat of battle, Mark's ability to distil and communicate the key points and create a consensus around the table exceeds any other lawyer I have worked with…"

Mark is a member of the Corporations Committee and the Foreign Investment Committee of the Law Council of Australia and the Advisory Committee of the Asia Society Australasia.

Experience

  • QIC takes AUD$128.47 million cornerstone stake in AUD$1.286 billion IPO of Dalrymple Bay Coal TerminalJones Day advised QIC Ltd in connection with its cornerstone investment in the proposed AUD$1.286 billion initial public offering on the Australian Securities Exchange of Dalrymple Bay Infrastructure Limited (DBI), the owner of the Dalrymple Bay Coal Terminal (DBCT) in Queensland, Australia, which is the world’s largest metallurgical coal export terminal.
  • PRP Diagnostic Imaging and PRP Group Investments sold to Crescent Capital PartnersJones Day advised PRP Diagnostic Imaging (PRP) and PRP Group Investments (PRPG) on the sale of PRP to private equity fund Crescent Capital Partners (Crescent).
  • GetSwift completes re-domicile to Canada’s NEO ExchangeJones Day acted as Australian legal advisor to GetSwift Limited in its "top hat" scheme of arrangement to create a new Canadian holding company and re-domicile from Australia to Canada, resulting in its delisting from ASX and a new listing on the NEO Exchange in Toronto.

  • Sasser Family Holdings sell CF Asia Pacific

    Sasser Family Holdings on the sale of rail locomotive and rolling stock business, CF Asia Pacific, to funds associated with Anchorage Capital Partners.

  • Centuria acquires Heathley Limited

    Centuria Group on the acquisition of a controlling interest in specialist healthcare funds manager, Heathley Limited, now Centuria Healthey.

  • Centuria Industrial REIT (CIP) unsuccessful takeover proposal from PropertylinkJones Day advised Centuria Industrial REIT (CIP) in the attempted A$755 million ($548.3 million) unsolicited indicative and non-binding proposal from Propertylink Group to acquire all of the units in Centuria Industrial REIT by way of an agreed off-market takeover offer.
  • KPMG Australia acquires Ferrier HodgsonJones Day advised KPMG Australia in its acquisition of Ferrier Hodgson, a leading independent restructuring, turnaround and insolvency firm in Australia.
  • Pepper Group acquired by KKR in A$675.9 million scheme of arrangementJones Day advised Pepper Group Limited ("Pepper") on the acquisition of a controlling interest in Pepper by way of scheme of arrangement by an affiliate of KKR, a leading global investment firm.
  • CIC Capital part of A$9.05 billion (US$6.75 billion) consortium for takeover of Asciano, one of the most complex transactions in Australia in recent times and largest deal in 2016Jones Day acted for CIC Capital Corporation on the A$9.05 billion (US$6.75 billion) takeover of rail and ports operator, Asciano, by a consortium including Brookfield, Qube Holdings, CPPIB, GIP, CIC Capital, GIC, Qatar Investment Authority, and bcIMC.
  • Highlands Pacific Limited defeats Board spill motionsJones Day advised Highlands Pacific Limited (HIG) on a Board spill requisition and subsequent special meeting of shareholders where the Board spill motions were defeated.
  • Cardinal Health acquires leading patient product portfolio from Medtronic for $6.1 billionJones Day advised Cardinal Health on the acquisition of Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash.
    • View All

    February 2021 Commentaries

    ASIC Signals Increasing Expectations for Climate Change Disclosures

    February 2021 Commentaries

    Slowing the Growth of Shareholder Class Actions? Australia Announces Permanent Changes to Continuous Disclosure Laws

    January 2021 Commentaries

    Significant Changes to Australia's Foreign Investment Framework Commenced on 1 January 2021

    December 2020 Commentaries

    Highlights From ASIC's December Corporate Finance Update

    November 2020 Newsletters

    Australian Company & Securities Update | Issue One

    September 2020 Alerts

    ASIC's Corporate Plan Persists With Its "Why Not Litigate" Approach to Enforcement

    August 2020 Commentaries

    ASIC v Mitchell: Another Reason for ASIC Not to Litigate

    April 2020 Commentaries

    COVID-19 and Australia's Foreign Investment Regime

    October 2019 Commentaries

    APRA v. IOOF—Key Issues for Australian Directors and Management

    October 2019 Alerts

    Australian IPOs and Takeovers: Liability Has Increased, Defences Are Eroded
    View All
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.